TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
NCT01281813 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 145
Last updated 2022-10-31
Summary
The primary objective of this trial is to continue the provision of darunavir/ low-dose ritonavir (DRV/rtv) to adult and pediatric patients who previously received DRV/rtv in the clinical trials TMC114-C211, TMC114-C214, TMC114-TiDP31-C229 or in the pediatric trial TMC114-TiDP29-C232 who continue to benefit from the use of darunavir in combination with low-dose ritonavir (DRV/rtv), in countries where DRV is not commercially available for the subject, is not reimbursed, or cannot be accessed through another source (e.g., access program, governmental program) and to provide DRV through this trial until the participants can switched to locally available DRV-based treatment regimens (that is commercially available and reimbursed, or accessible through another source \[for example, access program or government program\]) or to local standard of care, as appropriate.
Conditions
- HIV-1 Infections
Interventions
- DRUG
-
Darunavir
Participants will receive darunavir (per parent study) as oral suspension.
- DRUG
-
Ritonavir
Participants will receive ritonavir (per parent study) as oral solution/suspension.
Sponsors & Collaborators
-
Janssen Sciences Ireland UC
lead INDUSTRY
Principal Investigators
-
Janssen Sciences Ireland UC Clinical Trial · Janssen Sciences Ireland UC
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 3 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-08-08
- Primary Completion
- 2021-07-29
- Completion
- 2021-07-29
Countries
- Brazil
- Costa Rica
- Guatemala
- Malaysia
- Panama
- South Africa
- Thailand
- Ukraine
Study Locations
More Related Trials
-
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
NCT00110877 ·Status: COMPLETED ·Phase: PHASE3
-
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
NCT02494986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed
NCT04012931 ·Status: COMPLETED ·Phase: PHASE2
-
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
NCT00258557 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
NCT01620944 ·Status: TERMINATED ·Phase: PHASE3
-
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
NCT00896051 ·Status: COMPLETED ·Phase: PHASE2
-
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
NCT01605084 ·Status: WITHDRAWN ·Phase: PHASE3
-
Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors
NCT00543101 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
NCT00915655 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
NCT01705574 ·Status: COMPLETED ·Phase: PHASE3
-
Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine
NCT02284035 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
NCT01516970 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
NCT02473328 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
NCT00002045 ·Status: COMPLETED ·Phase: NA
-
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
NCT00144105 ·Status: TERMINATED ·Phase: PHASE2
-
Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children
NCT02383108 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety Study of Raltegravir in HIV/HCV Co-infected Patients
NCT01225705 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
NCT03198884 ·Status: COMPLETED
-
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
NCT00004578 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
NCT02227238 ·Status: COMPLETED ·Phase: PHASE3
-
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
NCT00272779 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
NCT01975012 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults
NCT03149211 ·Status: WITHDRAWN ·Phase: PHASE3